Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia
A Randomized and Open-label Dose-finding, Ph. 2, Efficacy, Safety, and Pharmacokinetic Study of Once-per-cycle Prophylactic Injections of ANF-RHO™ Versus Pegfilgrastim (Neulasta®) in Non-metastatic Breast Cancer Patients at High-risk of Chemotherapy-induced Neutropenia
Sponsor: Prolong Pharmaceuticals
Terminated
Study redesign
Other terminated trials from Prolong Pharmaceuticals
A PHASE2 clinical study on Chemotherapy-induced Neutropenia, this trial is terminated or withdrawn. The trial is conducted by Prolong Pharmaceuticals and has accumulated 5 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Mar 2019 — Jan 2021 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jul 2018 — Mar 2019 [monthly]
Recruiting PHASE2
First recorded
Aug 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Prolong Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .